Role of PCSK9 in hallmarks of cancer: From mechanisms to interventions (Review)
Oncology Letters · 15.07.2026 · 32 (3) · 1-17
DOI: 10.3892/ol.2026.15767 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Letters, online erschienen am 15.07.2026. Verfasst von Lijuan Tang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400432, P.R. China. Die Arbeit nennt 164 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400432, P.R. China.
- Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing 400432, P.R. China.
- Department of Nursing, Daping Hospital, Army Medical University, Chongqing 400432, P.R. China.
- Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing 400432, P.R. China.
- Obesity, Diabetes and Metabolism Laboratory, Biomedical Research Institute of Murcia, Murcia 30120, Spain.
- Department of Neurosurgery, Daping Hospital, Army Medical University, Chongqing 400432, P.R. China.
Zitieren
APA
Tang, L., Yao, S., Zhu, Y., He, Z., Ramos-Molina, B., & Xu, Y. (2026). Role of PCSK9 in hallmarks of cancer: From mechanisms to interventions (Review). Oncology Letters, 32(3), 1-17. https://doi.org/10.3892/ol.2026.15767
Vancouver
Tang L, Yao S, Zhu Y, He Z, Ramos-Molina B, Xu Y. Role of PCSK9 in hallmarks of cancer: From mechanisms to interventions (Review). Oncology Letters. 2026;32(3):1-17. doi:10.3892/ol.2026.15767
BibTeX
@article{Tang2026,
author = {Tang, Lijuan and Yao, Shu and Zhu, Yongheng and He, Zongsheng and Ramos-Molina, Bruno and Xu, Yuanchun},
title = {Role of PCSK9 in hallmarks of cancer: From mechanisms to interventions (Review)},
journal = {Oncology Letters},
year = {2026},
volume = {32},
number = {3},
pages = {1--17},
doi = {10.3892/ol.2026.15767}
}
EUVIMED